NEW YORK (GenomeWeb News) – Horizon Discovery said today that it has signed a commercial service agreement with GlaxoSmithKline in the area of cancer metabolomics.

Under the agreement, Cambridge, UK-based Horizon will use its X-MAN cell lines to provide GSK with services including the characterization of biomarkers, disease signatures, and therapeutic targets.

Financial terms of the agreement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.